James
banner
jamlee206.bsky.social
James
@jamlee206.bsky.social
Someone who spends too much time on tech, business, & stocks
The Clothing Company Outperforming Nvidia

Aritzia’s Q3 FY2026 was one of its best quarters ever—like a walk-off home run in the playoffs. For the first time in the company’s history, they crossed the CAD 1 billion revenue mark in a single quarter, hitting CAD 1.04 billion, up 42.8% YoY. Aritzia…
The Clothing Company Outperforming Nvidia
Aritzia’s Q3 FY2026 was one of its best quarters ever—like a walk-off home run in the playoffs. For the first time in the company’s history, they crossed the CAD 1 billion revenue mark in a single quarter, hitting CAD 1.04 billion, up 42.8% YoY. Aritzia grew sales by nearly 43% while increasing inventory by only 10%. This means their inventory turnover is accelerating and they're selling clothes almost as fast as they can get them off the trucks.
invest-in-myself.com
January 15, 2026 at 7:16 AM
Investment Thesis: LA Chargers 2026–27 Championship (Prediction Market Play)

Asset Class: NFL Event Contracts (e.g., Robinhood, Kalshi) Time Horizon: 12–14 Months Conviction Level: High (Conditional on Jesse Minter's retention) I. Executive Summary The market is currently mispricing the LA…
Investment Thesis: LA Chargers 2026–27 Championship (Prediction Market Play)
Asset Class: NFL Event Contracts (e.g., Robinhood, Kalshi) Time Horizon: 12–14 Months Conviction Level: High (Conditional on Jesse Minter's retention) I. Executive Summary The market is currently mispricing the LA Chargers due to recency bias following their 16–3 Wild Card exit. By applying first principles, I identify a massive gap between the "Playoff Loser" narrative and the reality of a team with elite QB talent, a top-tier coaching foundation, and the league's most aggressive potential for capital deployment in 2026 ($103M+).
invest-in-myself.com
January 12, 2026 at 7:13 AM
Revolve’s Superpowers: A Rare and Powerful Combination Most Investors Completely Overlook

Revolve Group (NYSE: RVLV) is the forgotten champion of apparel retail. While Wall Street obsesses over hyper-growth names and retail investors chase the next meme stock, Revolve quietly operates one of the…
Revolve’s Superpowers: A Rare and Powerful Combination Most Investors Completely Overlook
Revolve Group (NYSE: RVLV) is the forgotten champion of apparel retail. While Wall Street obsesses over hyper-growth names and retail investors chase the next meme stock, Revolve quietly operates one of the strongest, most defensible business models in the entire consumer sector. It’s dismissed as “just another overpriced clothing seller,” but that superficial take misses two genuine superpowers that are extraordinarily rare in the apparel sector.
invest-in-myself.com
December 11, 2025 at 6:06 AM
The Headline Trap: Why Moderna Wins with the Lower Number

Pfizer has released Phase 3 data for its mRNA flu vaccine, boasting 34% greater efficacy than the standard flu shot. On paper, this beats Moderna’s candidate, which demonstrated 26.6% efficacy. If you trade on headlines alone, you buy…
The Headline Trap: Why Moderna Wins with the Lower Number
Pfizer has released Phase 3 data for its mRNA flu vaccine, boasting 34% greater efficacy than the standard flu shot. On paper, this beats Moderna’s candidate, which demonstrated 26.6% efficacy. If you trade on headlines alone, you buy Pfizer. If you trade on first principles, you recognise the trap. The trials weren’t even testing the same thing. The Demographic Divergence: Premium vs.
invest-in-myself.com
December 3, 2025 at 8:27 AM
"It was unclear whether the members all understood what they were voting for." 🫥
September 19, 2025 at 12:11 AM
It appears the anti-vaxxers are not even the best and brightest from that community. What a clown show.
September 19, 2025 at 12:10 AM
If you have kids in school in FL, it's time to leave. It will be a cesspool of infectious diseases in a few years.
September 3, 2025 at 5:37 PM
Attempting to debate an anti-vaxxer on the merits of science and logic is like trying to make a bank deposit with monopoly money.
September 2, 2025 at 11:12 PM
3. Consensus of peer-reviewed and replicated studies is considered proof of a conspiracy. The more experts who agree, the more convinced they are that the corruption is widespread. Their "authority" is based on personal anecdotes.
September 2, 2025 at 11:09 PM
2. Burden of Proof fallacy: Making extraordinary claims - vaccines cause autism or death, yet demand you prove a negative, which is an impossible standard for any medical intervention.
September 2, 2025 at 11:06 PM
Fool's errand with debating an anti-vaxxer. 1. A constantly moving goal post: No study or body of evidence is good enough. It's either funded by Big Pharma or all scientists are part of a greater conspiracy
September 2, 2025 at 11:03 PM
UnitedHealth: Navigating the Fog of War in Healthcare

Investing in the U.S. healthcare sector is akin to navigating a battlefield shrouded in fog. Stocks like UnitedHealth (UNH), Oscar Health, Progyny, Hims & Hers Health, or even Novo Nordisk may seem appealing, but a minefield of uncertainties…
UnitedHealth: Navigating the Fog of War in Healthcare
Investing in the U.S. healthcare sector is akin to navigating a battlefield shrouded in fog. Stocks like UnitedHealth (UNH), Oscar Health, Progyny, Hims & Hers Health, or even Novo Nordisk may seem appealing, but a minefield of uncertainties surrounds them. I am skeptical whether UNH is the obvious value play. Picture this: Deploying your capital is like sending troops into hostile, unpredictable terrain.
invest-in-myself.com
August 13, 2025 at 4:24 AM
Is Lemonade (LMND) Becoming Dangerously Good?

Philadelphia Phillies starting pitcher Zack Wheeler As an investor, I've had a love-hate relationship with Lemonade stock. I loaded up too heavily right after its 2020 IPO, only to regret not buying more aggressively when shares dipped into single…
Is Lemonade (LMND) Becoming Dangerously Good?
Philadelphia Phillies starting pitcher Zack Wheeler As an investor, I've had a love-hate relationship with Lemonade stock. I loaded up too heavily right after its 2020 IPO, only to regret not buying more aggressively when shares dipped into single digits. If you're considering this name, approach it with caution—it's a classic high-risk, high-reward bet. Lemonade remains a young company in its growth phase, far from maturity.
invest-in-myself.com
August 11, 2025 at 7:30 AM
Tapestry (TPR): Deep Value to Cautious Optimism

In 2016, I invested in Tapestry (TPR), betting on Coach as an undervalued brand poised for a turnaround. It was one of the first stocks I bought as a new investor. My thesis was straightforward: the stock could reclaim its March 2012 peak of $79.70.…
Tapestry (TPR): Deep Value to Cautious Optimism
In 2016, I invested in Tapestry (TPR), betting on Coach as an undervalued brand poised for a turnaround. It was one of the first stocks I bought as a new investor. My thesis was straightforward: the stock could reclaim its March 2012 peak of $79.70. Nearly a decade later, my prediction proved correct, though the road was far from smooth.
invest-in-myself.com
August 9, 2025 at 6:41 AM
Lol
August 4, 2025 at 8:39 PM
Why Palantir Reminds Me of Gangnam Style

Palantir redefined data analytics, while Gangnam Style redefined K-pop. Both achieved unexpected success through unconventional approaches, capitalizing on the right timing, transformative momentum, and cultural context. Palantir, whose stock has surged…
Why Palantir Reminds Me of Gangnam Style
Palantir redefined data analytics, while Gangnam Style redefined K-pop. Both achieved unexpected success through unconventional approaches, capitalizing on the right timing, transformative momentum, and cultural context. Palantir, whose stock has surged over 400% in the past year, has become a focal point in the AI movement, despite its 20-year history. Similarly, Psy was already a veteran artist in South Korea, having started his career in 1999, 13 years before the global phenomenon' Gangnam Style' was released in 2012.
invest-in-myself.com
July 31, 2025 at 9:02 AM
Profitability with rapidly accelerating growth rates. Please stop comparing it with unprofitable companies.
February 11, 2025 at 4:31 AM
How can you value a company accurately if you do not know what they sell? In the market they are in, who are their competitors? Do you know the answer to that question?
February 10, 2025 at 5:44 PM
It is simplistic to dismiss it as a "meme stock" or "overvalued." Its unique position in a nascent industry without direct competitors makes traditional comparisons difficult. Furthermore, its commercial business is still in the early stages of development.
February 8, 2025 at 8:56 AM
These metrics suggest the company is a top performer and requires a more nuanced valuation approach. Lumping PLTR with DJT and GME is not even remotely in the same ballpark.
February 8, 2025 at 8:52 AM
Your analysis overlooks the company's exceptional growth. U.S. commercial revenue grew by 54%, and free cash flow margins have exceeded 50% for two quarters. This is significantly higher than SaaS companies' typical 20-30%.
February 8, 2025 at 8:43 AM
Ai enterprise software. Ask the companies that use it - Airbus, Tampa Bay General Health, United Health, etc.
February 4, 2025 at 8:56 PM
Pltr isn't a meme stock. Look at the fundamentals.
February 4, 2025 at 4:50 AM